AbbVie Inc. (NYSE:ABBV)
- CEO:Richard A. Gonzalez
AbbVie Inc. (NYSE:ABBV) Stock Price
Disclaimer: Past performance is not an indicator of future performance.
AbbVie Inc. (NYSE:ABBV) Company Overview
Born in 2013, Abbvie is a research-focused biopharmaceutical company with a drive to do more than just treat disease. Aiming to make a 'remarkable impact on people's lives,' the company has been developing new approaches to addressing current health issues for over 30 million patients across nearly 200 countries.
In 2016 Abbvie introduced Marinol (dronabinol) the first cannabinoid-based prescription medicine approved by the FDA for use in patients that don't respond to standard medication. However, on 31 December 2019, Alkem Laboratories announced it would acquire the anti-nausea drug for US$10 million.
Employing nearly 50,000 employees made up of scientists, researchers, communicators, manufacturing specialists and regulatory experts from around the world.
The company owns and operates 22 primary research and manufacturing facilities around the world, with close to 300 patient support programs in operation.
Operational revenue grew 2.7% to US$33.3billion in 2019, operating earnings of $13.0 billion, diluted earnings per share of $5.28 and cash flow from
operations of $13.3 billion.
- Address:1 North Waukegan Road North Chicago, IL 60064 United States
- Phone No.:847 932 7900